eCite Digital Repository

Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?

Citation

Nikpour, M and Stevens, W and Proudman, SM and Buchbinder, R and Prior, D and Zochling, J and Williams, T and Gabbay, E and Nandurkar, H, Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?, Internal Medicine Journal, 43, (5) pp. 599-603. ISSN 1444-0903 (2013) [Refereed Article]

Copyright Statement

Copyright 2013 The Authors

DOI: doi:10.1111/imj.12111

Abstract

Pulmonary arterial hypertension (PAH) is a major cause of mortality in scleroderma and despite 'advanced' therapies confers a median survival of less than 5 years. Anticoagulation in systemic sclerosis-related PAH (SSc-PAH) is currently one of the most contentious issues in the management of patients with connective tissue disease. While some studies have shown a survival benefit with warfarin therapy in this disease, others have not. Accordingly, a state of clinical equipoise exists in relation to anticoagulation in SSc-PAH. With an over fivefold reduction in mortality demonstrated in some observational studies, the issue of anticoagulation in SSc-PAH demands resolution through a well-designed randomised controlled trial. © 2013 Royal Australasian College of Physicians.

Item Details

Item Type:Refereed Article
Keywords:scleroderma, systemic sclerosis, pulmonary arterial hypertension, anticoagulation, randomised controlled trial
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Rheumatology and Arthritis
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Skeletal System and Disorders (incl. Arthritis)
Author:Zochling, J (Dr Jane Zochling)
ID Code:84919
Year Published:2013
Web of Science® Times Cited:9
Deposited By:Menzies Institute for Medical Research
Deposited On:2013-06-06
Last Modified:2017-11-02
Downloads:0

Repository Staff Only: item control page